Trials / Completed
CompletedNCT01060579
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A Phase 2, Double-masked, Randomized, Active-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 217 (actual)
- Sponsor
- Aerie Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be different from that of an active control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AR-12286 0.5% ophthalmic solution | q.d. PM |
| DRUG | AR-12286 0.25% Ophthalmic solution | q.d. PM |
| DRUG | Latanoprost ophthalmic solution | q.d. PM |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2010-02-02
- Last updated
- 2014-05-08
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01060579. Inclusion in this directory is not an endorsement.